Wednesday, 17 August 2022
Meet the JournalistsPremiumAucklandWellingtonCanterbury/South Island
CrimePoliticsHealthEducationEnvironment and ClimateNZ Herald FocusData journalismKāhu, Māori ContentPropertyWeather
Small BusinessOpinionPersonal FinanceEconomyBusiness TravelCapital Markets
Politics
Premium SportRugbyCommonwealth GamesCricketRacingNetballBoxingLeagueFootballSuper RugbyAthleticsBasketballMotorsportTennisCyclingGolfAmerican SportsHockeyUFC
NZH Local FocusThe Northern AdvocateThe Northland AgeThe AucklanderWaikato HeraldBay of Plenty TimesHawke's Bay TodayRotorua Daily PostWhanganui ChronicleStratford PressManawatu GuardianKapiti NewsHorowhenua ChronicleTe Awamutu Courier
Covid-19
Te Rito
Te Rito
OneRoof PropertyCommercial Property
Open JusticeVideoPodcastsTechnologyWorldOpinion
SpyTVMoviesBooksMusicCultureSideswipeCompetitions
Fashion & BeautyFood & DrinkRoyalsRelationshipsWellbeingPets & AnimalsVivaCanvasEat WellCompetitionsRestaurants & Menus
New Zealand TravelAustralia TravelInternational Travel
Our Green FutureRuralOneRoof Property
Career AdviceCorporate News
Driven MotoringPhotos
SudokuCodecrackerCrosswordsWordsearchDaily quizzes
Classifieds
KaitaiaWhangareiDargavilleAucklandThamesTaurangaHamiltonWhakataneRotoruaTokoroaTe KuitiTaumarunuiTaupoGisborneNew PlymouthNapierHastingsDannevirkeWhanganuiPalmerston NorthLevinParaparaumuMastertonWellingtonMotuekaNelsonBlenheimWestportReeftonKaikouraGreymouthHokitikaChristchurchAshburtonTimaruWanakaOamaruQueenstownDunedinGoreInvercargill
NZ HeraldThe Northern AdvocateThe Northland AgeThe AucklanderWaikato HeraldBay Of Plenty TimesRotorua Daily PostHawke's Bay TodayWhanganui ChronicleThe Stratford PressManawatu GuardianKapiti NewsHorowhenua ChronicleTe Awamutu CourierVivaEat WellOneRoofDriven MotoringThe CountryPhoto SalesNZ Herald InsightsWatchMeGrabOneiHeart RadioRestaurant Hub

Advertisement

Advertise with NZME.
Business

Opinion: What should investors be looking out for in healthcare sector growth exposures?

22 May, 2021 03:00 AM6 minutes to read
F&P Healthcare and Ryman have been standouts among Australasian healthcare companies. Photo / 123RF

F&P Healthcare and Ryman have been standouts among Australasian healthcare companies. Photo / 123RF

NZ Herald
By Arie Dekker and Steve Wheen

OPINION:

Across Australia and New Zealand there are a number of large capitalisation healthcare companies that have delivered strong and consistent valuation growth over the past 10 years including Fisher & Paykel Healthcare, Ryman Healthcare, CSL, Cochlear and Ramsay Healthcare.

Two standouts in New Zealand have been F&P Healthcare and Ryman.

F&P Healthcare's global market opportunity contrasts with Ryman's focus on New Zealand and Victoria, Australia to date. The research & development focus for F&P Healthcare also differs from Ryman's capital-intensive infrastructure healthcare asset base.

But there are similarities too, which include large addressable markets, products and services based on needs linked to favourable demographics and healthcare trends, very strong customer proposition, and great execution.

Read More

  • Fisher & Paykel Healthcare profit surges on Covid demand - NZ Herald
  • Deloitte Top 200: Fisher & Paykel Healthcare named Company of the Year - NZ Herald
  • Gordon MacLeod to quit Ryman Healthcare, record sales yield 60% profit rise - NZ Herald
  • Ryman wins consent for $150m Kohimarama village under new Covid fast-track legislation - NZ Her...

If we extend the universe of large-cap healthcare stocks to include Australia, investors have been spoilt, with choice with CSL, Cochlear and Ramsay Healthcare all delivering meaningful growth in market capitalisation during the past decade.

CSL is unique in this Australasian context and is a leading global biotechnology company involved in the development and delivery of innovative biotherapies and influenza vaccines. Despite its larger scale, it has grown at a similar rate to Ryman during the past 10 years. Its market capitalisation has grown from $25 billion to $135b over that period. During the same period, F&P Healthcare's market valuation went from $1.6b to $19b while Ryman's grew from $1.3b to $7.2b.

Cochlear has more in common with F&P Healthcare. CSL, Cochlear and F&P Healthcare's success has been closely linked to their ability to monetise intellectual property with consistent investment in Research & Development. F&P Healthcare invests about 8-10 per cent of revenue each year – now well over $100 million in Research & Development annually.

Advertisement

Advertise with NZME.

F&P Healthcare has low asset intensity, with total assets sitting at around 1x revenue which has helped support its organic growth. F&P Healthcare has not raised any meaningful equity capital over the past 10 years and has been able to grow dividends while expanding its manufacturing capacity for growing demand and maintaining low levels of debt – indeed F&P Healthcare is currently in a net cash position.

Ryman's market capitalisation has grown from $1.3b to $7.2b over the past 10 years. Photo / NZME
Ryman's market capitalisation has grown from $1.3b to $7.2b over the past 10 years. Photo / NZME

The funding models supporting sales for CSL, Cochlear and F&P Healthcare are all very robust. For CSL, a combination of the scarcity and superior efficacy/safety of its product generates a level of pricing that is seldom under pressure especially while there is a tightness in supply. Similarly, Cochlear and F&P Healthcare sell into an established hospital channels that have seen little price compression.

Related articles

New Zealand|Politics

'Keeping an open mind': PM on border re-opening

21 May 05:00 PM
Business

Sharemarket in punishing mood despite decent company results

21 May 05:53 AM
Business

Fran O'Sullivan: Collins' tightrope act deserves more applause

21 May 07:00 PM
Business

Steven Joyce: The magical assumptions around house prices

21 May 05:00 PM

Ryman and Ramsay are both involved in the provision of healthcare services. Their business models rely on healthcare infrastructure rather than intellectual property to provide services and generate returns. In particular, Ryman has a high level of asset intensity with total assets over 10x statutory reported revenue.

That greater capital intensity impacts the balance sheet. Ramsay has meaningful bank debt and right of use liabilities on its balance sheet. While it had managed to grow without raising equity for a long time, it had to do a meaningful capital raise last year to stabilise its global balance sheet at a time of great uncertainty around Covid. Ramsay went hard and early on the capital raise.

Despite the asset intensity, one of the major attractions in Ryman's business model has been its ability to grow without raising capital in the past 10 years.

Ryman has raised no equity in the past 10 years and the growth in its market value reflects an efficient growth funding model for equity investors. There are three key drivers behind this:

• Its retirement village model sees residents fund the completed units it develops by way of interest-free loans in return for the right to occupy.

• Ryman is an efficient developer and is generally able to fund its care facilities through the development profits from selling occupation rights to retirement village units.

Advertisement

Advertise with NZME.

• It has been able to source a quickly growing amount of bank debt (from $545m in FY16 to $1.7b in FY20) to fund its development.

While it hasn't grown as strongly as F&P Healthcare, Ryman has also been able to grow its dividend. The growth in the absolute scale of Ryman's asset base is driving some changes in funding asset growth.

Ryman has begun diversifying its funding sources away from the banks and the introduction of accommodation bonds in New Zealand will see it borrow from care patients. These things should help keep the development engine running without the need for equity for some time.

F&P Healthcare designs, makes and markets products respiratory systems. Photo / NZME
F&P Healthcare designs, makes and markets products respiratory systems. Photo / NZME

Whereas F&P Healthcare and its peers have experienced little pressure on funding for their products, this has been a factor weighing on Ramsay more recently (reimbursement; reduction in private insurance in Australia coupled with wage pressure). Ryman also has some issues with the care funding model in New Zealand that are impacting its statutory operating profitability. It appears that care funding has not been keeping up with the increasing costs associated with provision of care services.

These Australasian healthcare companies look well placed to continue to benefit from strong fundamentals in the market and strong execution. We expect the rate of market valuation growth to be influenced by intellectual property and the ability to protect it through R&D – critical for F&P Healthcare and its peers; asset intensity (premiums for lower asset/capital intensity business models more likely); and funding models. When we look out five years, we see strong growth in the earnings and dividends these businesses generate.

In the case of F&P Healthcare, CSL and Cochlear we see the ability to grow without taking on more debt. Meanwhile, Ryman continues to be well placed on its objective to double its underlying assets every five years but this will come with meaningful growth in the amount it needs to borrow from capital providers, its residents and care patients.

• Arie Dekker and Steve Wheen are analysts at Jarden.

This article reflects the opinions and views at the time of publication, and is not to be relied upon as a basis for making any investment decision. Please seek specific investment advice before making any investment decision. Jarden Securities Limited is an NZX Firm, a financial advice provider disclosure statement is available free of charge at www.jarden.co.nz. Jarden is not a registered bank in New Zealand.

Advertisement

Advertise with NZME.

Latest from Business

BusinessUpdated

Will Costco change how Kiwis shop? How to get the most out of buying in bulk

16 Aug 10:34 PM
Premium
Business

Crypto fail: Kickstarter fury as NZ firm raises $1m, game fails to appear

16 Aug 10:22 PM
Premium
BusinessUpdated

'Turning point': Property resale gains not the usual 'cash windfall'

16 Aug 09:00 PM
Business

Tourism NZ teaser adverts for those who don't eat two-minute noodles

16 Aug 09:00 PM
Video

Tourism NZ launches first global campaign in two years

Most Popular

NZ's low literacy rate is bad news for the economy
Education

NZ's low literacy rate is bad news for the economy

16 Aug 08:12 PM
Chlöe Swarbrick: We can choose to rewrite the rules again
New Zealand|Politics

Chlöe Swarbrick: We can choose to rewrite the rules again

16 Aug 05:00 PM
Premium
Matt Heath: Life is short and the universe doesn't care, so make the most of it
Lifestyle

Matt Heath: Life is short and the universe doesn't care, so make the most of it

16 Aug 05:00 PM

Advertisement

Advertise with NZME.
About NZMEHelp & SupportContact UsSubscribe to NZ HeraldHouse Rules
Manage Your Print SubscriptionNZ Herald E-EditionAdvertise with NZMEBook Your AdPrivacy Policy
Terms of UseCompetition Terms & ConditionsSubscriptions Terms & Conditions
© Copyright 2022 NZME Publishing Limited
TOP